



MEN

FIRST CANCER SITE  
**HODGKIN  
LYMPHOMA**

**HODGKIN LYMPHOMA  
POOL AIRTUM 1976-2010, MEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**LINFOMA DI HODGKIN  
POOL AIRTUM 1976-2010, UOMINI:**

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	5378		5615		5615		5378		4676		2677		1321		5378	5615
Person-years ▶	35127		36042		915		4171		14201		9671		7085		35127	36042
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND HODGKIN LYMPHOMA	311	1.59	327	1.63	16	2.83	23	0.99	115	1.57	71	1.35	102	2.21	3.30	3.50
HEAD AND NECK	15	1.44	16	1.49	1	3.43	0	0.00	7	1.76	4	1.44	4	1.65	0.13	0.15
ORAL CAVITY	6	2.29	6	2.23	0	0.00	0	0.00	2	2.05	3	4.24	1	1.56	0.10	0.09
PHARYNX	3	1.18	4	1.53	1	15.08	0	0.00	2	2.11	1	1.46	0	0.00	0.01	0.04
LARYNX	6	1.14	6	1.11	0	0.00	0	0.00	3	1.46	0	0.00	3	2.60	0.02	0.02
OESOPHAGUS	7	3.13	8	3.47	1	15.33	0	0.00	1	1.18	0	0.00	6	11.34	0.14	0.16
STOMACH	15	1.39	15	1.35	0	0.00	1	0.70	4	0.94	5	1.77	5	2.19	0.12	0.11
COLON RECTUM	28	1.11	28	1.08	0	0.00	1	0.33	10	1.07	7	1.03	10	1.64	0.08	0.06
COLON	16	0.95	16	0.92	0	0.00	0	0.00	4	0.64	4	0.88	8	1.94	-0.02	-0.04
RECTUM	12	1.43	12	1.39	0	0.00	1	0.99	6	1.91	3	1.33	2	1.01	0.10	0.09
LIVER	10	1.32	10	1.28	0	0.00	3	3.33	6	2.11	0	0.00	1	0.55	0.07	0.06
GALLBLADDER	3	1.70	3	1.64	0	0.00	0	0.00	1	1.49	0	0.00	2	4.95	0.04	0.03
PANCREAS	10	2.01	10	1.95	0	0.00	0	0.00	4	2.16	1	0.75	5	4.15	0.14	0.14
LUNG	72	2.22	77	2.31	5	5.00	2	0.49	27	2.14	16	1.86	27	3.80	1.13	1.21
SKIN MELANOMA	8	1.72	8	1.68	0	0.00	0	0.00	1	0.60	2	1.54	5	4.10	0.10	0.09
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
KAPOSI SARCOMA	3	4.68	3	4.56	0	0.00	2	27.30	1	4.06	0	0.00	0	0.00	0.07	0.06
SOFT TISSUE	2	1.93	2	1.88	0	0.00	0	0.00	1	2.56	1	3.55	0	0.00	0.03	0.03
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
BREAST	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
PROSTATE	36	1.13	36	1.10	0	0.00	3	0.82	10	0.87	7	0.82	16	1.93	0.12	0.09
TESTIS	2	0.76	2	0.75	0	0.00	0	0.00	1	0.96	1	1.31	0	0.00	-0.02	-0.02
KIDNEY AND RENAL PELVIS	9	1.29	11	1.54	2	10.85	2	2.56	2	0.78	3	1.59	2	1.15	0.06	0.11
BLADDER AND URINARY TRACT	21	1.03	24	1.14	3	4.91	2	0.80	7	0.91	7	1.28	5	1.07	0.02	0.08
URINARY BLADDER	21	1.07	24	1.19	3	5.11	2	0.83	7	0.94	7	1.33	5	1.11	0.04	0.11
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
BRAIN AND CENTRAL NERVOUS SYSTEM	2	0.60	2	0.59	0	0.00	0	0.00	2	1.58	0	0.00	0	0.00	-0.04	-0.04
THYROID	9	4.18	10	4.54	1	20.94	0	0.00	3	3.86	2	3.33	4	7.16	0.19	0.22
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
NON-HODGKIN LYMPHOMA	28	3.93	29	3.96	1	5.31	3	3.73	12	4.51	7	3.59	6	3.50	0.59	0.60
MYELOMA	3	1.24	3	1.20	0	0.00	1	3.44	1	1.11	1	1.54	0	0.00	0.02	0.01
LEUKAEMIAS	15	3.11	16	3.22	1	6.97	1	1.69	10	5.41	3	2.32	1	0.92	0.29	0.31
LYMPHOID LEUKAEMIAS	2	0.87	3	1.26	1	14.58	0	0.00	1	1.13	1	1.63	0	0.00	-0.01	0.02
MYELOID LEUKAEMIAS	12	5.42	12	5.26	0	0.00	1	3.74	8	9.48	2	3.33	1	1.99	0.28	0.27
OTHER LEUKAEMIAS	1	3.32	1	3.21	0	0.00	0	0.00	1	8.32	0	0.00	0	0.00	0.02	0.02
OTHER AND ILL DEFINED SITES	13	1.32	14	1.38	1	3.37	2	1.65	4	1.07	4	1.51	3	1.31	0.09	0.11

Decrease/Difetto    O Observed cases    SIR Standardized Incidence Ratio    EAR Excess Absolute Risk  
Increase/Eccesso    Casi osservati    Rapporto standardizzato di incidenza    Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE  
**HODGKIN  
LYMPHOMA**

**HODGKIN LYMPHOMA  
POOL AIRTUM 1976-2010, WOMEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**LINFOMA DI HODGKIN  
POOL AIRTUM 1976-2010, DONNE:**

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	4685	4850		4850		4685		4074		2443		1252		4685	4850
Person-years ▶	31941	32736		795		3633		12696		9154		6458		31941	32736	
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND HODGKIN LYMPHOMA	251	1.94	256	1.93	5	1.53	17	1.23	74	1.59	70	1.91	90	2.76	3.81	3.77
HEAD AND NECK	4	2.38	4	2.32	0	0.00	0	0.00	2	3.36	1	2.10	1	2.29	0.07	0.07
ORAL CAVITY	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
PHARYNX	4	8.84	4	8.64	0	0.00	0	0.00	2	12.70	1	7.80	1	8.25	0.11	0.11
LARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
OESOPHAGUS	1	2.16	1	2.10	0	0.00	0	0.00	0	0.00	0	0.00	1	9.14	0.02	0.02
STOMACH	6	1.09	6	1.06	0	0.00	1	1.40	3	1.41	1	0.67	1	0.87	0.02	0.01
COLON RECTUM	20	1.28	20	1.24	0	0.00	3	1.68	6	1.05	5	1.15	6	1.59	0.14	0.12
COLON	18	1.63	18	1.59	0	0.00	3	2.38	5	1.24	5	1.63	5	1.87	0.22	0.20
RECTUM	2	0.43	2	0.42	0	0.00	0	0.00	1	0.59	0	0.00	1	0.90	-0.08	-0.08
LIVER	2	0.85	2	0.82	0	0.00	0	0.00	2	2.24	0	0.00	0	0.00	-0.01	-0.01
GALLBLADDER	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.06	-0.06
PANCREAS	5	1.40	5	1.36	0	0.00	0	0.00	2	1.52	1	1.01	2	2.35	0.04	0.04
LUNG	24	3.59	24	3.50	0	0.00	0	0.00	6	2.53	7	3.75	11	6.40	0.54	0.52
SKIN MELANOMA	11	2.51	11	2.46	0	0.00	1	2.44	4	2.60	6	4.59	0	0.00	0.21	0.20
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
KAPOSI SARCOMA	1	7.00	1	6.79	0	0.00	0	0.00	0	0.00	0	0.00	1	33.61	0.03	0.03
SOFT TISSUE	6	8.46	6	8.26	0	0.00	0	0.00	0	0.00	4	19.75	2	11.90	0.17	0.16
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
BREAST	71	1.73	71	1.69	0	0.00	3	0.76	17	1.20	13	1.10	38	3.40	0.94	0.89
CERVIX UTERI	2	0.67	2	0.65	0	0.00	0	0.00	0	0.00	2	2.28	0	0.00	-0.03	-0.03
CORPUS UTERI	6	1.00	6	0.98	0	0.00	0	0.00	3	1.41	2	1.19	1	0.64	0.00	0.00
OVARY	4	0.89	4	0.87	0	0.00	1	2.08	0	0.00	3	2.34	0	0.00	-0.02	-0.02
KIDNEY AND RENAL PELVIS	10	3.59	11	3.86	1	14.22	4	13.51	4	4.01	0	0.00	2	2.85	0.23	0.25
BLADDER AND URINARY TRACT	9	2.41	9	2.35	0	0.00	0	0.00	1	0.73	3	2.89	5	5.63	0.17	0.16
URINARY BLADDER	8	2.29	8	2.23	0	0.00	0	0.00	1	0.78	3	3.09	4	4.80	0.14	0.13
URINARY TRACT	1	4.19	1	4.06	0	0.00	0	0.00	0	0.00	0	0.00	1	18.32	0.02	0.02
BRAIN AND CENTRAL NERVOUS SYSTEM	2	0.97	2	0.95	0	0.00	0	0.00	1	1.30	1	1.71	0	0.00	0.00	0.00
THYROID	12	2.05	14	2.34	2	17.80	1	1.90	3	1.48	6	3.43	2	1.28	0.19	0.25
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
NON-HODGKIN LYMPHOMA	23	4.77	23	4.65	0	0.00	1	1.92	8	4.54	6	4.37	8	6.86	0.57	0.55
MYELOMA	2	1.16	2	1.13	0	0.00	2	10.05	0	0.00	0	0.00	0	0.00	0.01	0.01
LEUKAEMIAS	20	7.01	20	6.82	0	0.00	0	0.00	8	7.39	8	10.04	4	6.30	0.54	0.52
LYMPHOID LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
MYELOID LEUKAEMIAS	19	12.72	19	12.39	0	0.00	0	0.00	8	14.34	8	18.95	3	8.68	0.55	0.53
OTHER LEUKAEMIAS	1	4.95	1	4.79	0	0.00	0	0.00	0	0.00	0	0.00	1	24.63	0.02	0.02
OTHER AND ILL DEFINED SITES	10	1.34	12	1.56	2	9.20	0	0.00	4	1.43	1	0.48	5	2.91	0.08	0.13

Decrease/Difetto / Increase/Eccesso    O Observed cases / Casi osservati    SIR Standardized Incidence Ratio / Rapporto standardizzato di incidenza    EAR Excess Absolute Risk / Eccesso assoluto di rischio